TY - JOUR
T1 - Immune checkpoint blockade
T2 - A common denominator approach to cancer therapy
AU - Topalian, Suzanne L.
AU - Drake, Charles G.
AU - Pardoll, Drew M.
N1 - Publisher Copyright:
© 2015 Elsevier Inc.
PY - 2015/4/13
Y1 - 2015/4/13
N2 - The immune system recognizes and is poised to eliminate cancer but is held in check by inhibitory receptors and ligands. These immune checkpoint pathways, which normally maintain self-tolerance and limit collateral tissue damage during anti-microbial immune responses, can be co-opted by cancer to evade immune destruction. Drugs interrupting immune checkpoints, such as anti-CTLA-4, anti-PD-1, anti-PD-L1, and others in early development, can unleash anti-tumor immunity and mediate durable cancer regressions. The complex biology of immune checkpoint pathways still contains many mysteries, and the full activity spectrum of checkpoint-blocking drugs, used alone or in combination, is currently the subject of intense study.
AB - The immune system recognizes and is poised to eliminate cancer but is held in check by inhibitory receptors and ligands. These immune checkpoint pathways, which normally maintain self-tolerance and limit collateral tissue damage during anti-microbial immune responses, can be co-opted by cancer to evade immune destruction. Drugs interrupting immune checkpoints, such as anti-CTLA-4, anti-PD-1, anti-PD-L1, and others in early development, can unleash anti-tumor immunity and mediate durable cancer regressions. The complex biology of immune checkpoint pathways still contains many mysteries, and the full activity spectrum of checkpoint-blocking drugs, used alone or in combination, is currently the subject of intense study.
UR - http://www.scopus.com/inward/record.url?scp=84928062583&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84928062583&partnerID=8YFLogxK
U2 - 10.1016/j.ccell.2015.03.001
DO - 10.1016/j.ccell.2015.03.001
M3 - Review article
C2 - 25858804
AN - SCOPUS:84928062583
SN - 1535-6108
VL - 27
SP - 450
EP - 461
JO - Cancer cell
JF - Cancer cell
IS - 4
ER -